Featured Commentaries
ICER Analytics as an ESG Investor Scorecard
This perspective, written by David Whitrap, was first shared in our Weekly View e-newsletter, which summarizes the week’s most significant drug pricing news. To subscribe, click here. This week, Bernstein’s biopharma analyst Ronny Gal published an investor note titled: “ICER Analytics – the ultimate pharma ESG tool? Which companies are most exposed to fair pricing legislation?” In […]
05/14/2021An ICER Podcast: A Prescription for Fair Drug Pricing
Neurologist Dr. Jason Crowell sits down with ICER’s President Dr. Steve Pearson to pry open the black box of US drug pricing and to wrestle with each of the financial and ethical tensions that undergird our current medical infrastructure.
11/10/202012 facts to ponder about the Aduhelm approval
This perspective, written by David Whitrap, was first shared in our Weekly View e-newsletter, which summarizes the week’s most significant drug pricing news. To subscribe, click here. Undoubtedly, the week’s biggest news was the FDA’s approval of Biogen’s Aduhelm for the treatment of Alzheimer’s disease. ICER has already issued a statement sharing our reaction, but here’s a […]
06/11/2021